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 Cardiac Troponin - Diagnostic Problems and Impact on 
Cardiovascular Disease 
The definition of a high-sensitivity cardiac Troponin (cTn) assay describes the ability to 
quantify a cardiac biomarker level in at least 50% of healthy individuals. This advance in 
analytic sensitivity has come with a perceived loss of specificity in the most classic 
application – chest pain triage and the diagnosis of acute myocardial infarction (AMI). As 
cardiac Troponin can no longer be used as a dichotomous test, the medical field is 
increasingly moving towards a more granular interpretation. However, rapid rule-out/rule-in 
algorithms for AMI still rely on concrete thresholds for efficient triage, irrespective of the 
patient’s comorbidities. Owing to a slightly elevated cTn value, evermore patients appear to 
fall into an indeterminate risk zone of diagnostic uncertainty. The reasons are manifold, 
spanning biological variation, analytical issues, increased plasma membrane permeability and 
the potential cytosolic release of cTn. This review provides a contemporary overview of the 
literature concerning the use of cardiac Troponin in chronic and acute cardiovascular care. 
Keywords: cardiac Troponin; cardiovascular disease; acute myocardial infarction; biological 
variation; renal dysfunction 
Key messages: 
High-sensitivity cardiac Troponin assays have transformed the assessment of cardiovascular 
disease. 
Rapid rule-out algorithms for chest pain triage have become increasingly complicated, but 
enable safe rule-out. 
Cardiac Troponin tracks mid- to long-term risk in patients with hyperlipidaemia, heart failure 
and renal dysfunction. 
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‘Troponitis’ – is the colloquial term used by many clinicians to describe a falsely elevated 
(read: ‘false-positive’), cardiac Troponin (cTn) result. But does such a condition actually 
exist? In this review we examine the use and abuse of high-sensitivity cardiac Troponin (hs-
cTn) testing. By dissecting the analytic path into its components, we hope to shed light on 
terms such as “troponitis” and reveal they are the inevitable consequence of extreme analytic 
sensitivity . Further, there are numerous applications and clinical scenarios, in which high-
sensitivity cardiac Troponin (hs-cTn) testing is well established and promises improved risk 
stratification, albeit with the caveat of some decrease in specificity and “troponitis”.  Firstly 
we will deal with the issue of analytic false-positive troponins, conditions where the assay 
“misfires” as a result of an analytic error. 
Known pre-analytic issues usually affect cTn values through interference with the laboratory 
assay: haemolysis and bilirubin interference can lead to falsely low cTnT concentrations, the 
mechanism, however, remains largely undiscovered.(1,2) Antibodies from an endogenous 
source can interfere with the assay, but are felt to be comparably rare and can cause – through 
interference with either the cTn complex or the (hs-)cTn assay – negative or positive 
interference.(3,4) Biotin, which is frequently used in supplements available over-the-counter, 
can further interfere with biotin-streptavidin based assays – and depending on the assay 
formulation (competitive versus sandwich methods), this can lead to falsely low (cTn) results 
(5) – but rarely can also result in false-positives. Finally, skeletal muscle disease, such as 
most recently described by Schmid et al. (6,7), can lead to an elevated cTnT concentration 
(but rarely cTnI), either through cross-reaction of the assay or, less convincing, a re-
expression of the cardiac isoform in diseased skeletal muscle. Other than in the latter cohort, 
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 which should be clinically distinguishable, why do clinicians see many more patients with 
quantifiable cTn concentrations, who do not suffer an acute decompensation of a 
cardiovascular condition?  
The sensitivity/specificity quagmire 
Owing to greater tissue selectivity, cardiac Troponin replaced creatine kinase-MB as the 
biomarker of choice for the triage of patients presenting with chest pain, and the subsequent 
diagnosis (or rule-out) of Non-ST elevation Myocardial Infarction (NSTEMI).(8,9) Due to a 
slow release pattern it was, however, inherently unsuited for the early detection of myocardial 
injury. (10,11) To overcome this biological handicap, the sensitivity of the assays had to 
increase. Today’s very definition of a hs-cTn assay – according to the International 
Federation of Clinical Chemistry and Laboratory Medicine Task Force on Clinical 
Applications of cardiac Bio-Markers (IFCC TF-CB) – includes 1) a CV ≤10% at the 99th 
centile value and 2) the ability to measure at least 50% of healthy individuals with 
concentrations above the assay’s Limit of Detection (LoD).(12,13) As high-sensitivity assays 
yield quantifiable results in a majority of healthy individuals (14,15), the use of a 99
th
 centile 
of a normal reference population to define a cut-off for normal vs abnormal becomes 
challenging in clinical day-to-day practice when it is applied to “unhealthy” patients in an 
attempt to diagnose acute myocardial infarction. The subsequent review of the literature 
will define the many caveats one encounters upon interpretation of cardiac Troponin results 
in this brave new world of high-, and imminent ultra-, sensitive assays. 
Analytical precision and biological variation of cTn 
For many applications of cTn in clinical practise, guidelines recommend the interpretation of 
baseline/presentation values plus a potential dynamic rise or fall (delta-change) of the 
biomarker over the clinical course.(16,17) This aids the distinction of AMI (as cause for an 
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 acute myocardial injury) vs chronic causes of cTn elevation, as a single elevated level 
appears insufficient to make a diagnosis of the former. The interpretation of release kinetics 
appears justified, as a recent publication has demonstrated that the limit of detection of hs-
cTn assays might be breached by necrosis of as little as 9 mg of myocardial tissue – too small 
to be detected by today’s imaging techniques.(18) The guidelines advocate the use of either 
relative or absolute changes from baseline cTn concentrations to define a dynamic change, 
whereas the latter appears to be more accurate in the diagnosis of AMI (19) and is endorsed 
in the 2015 ESC 0/1h NSTEMI rule-out pathway.(17) The recommended delta-change values 
are comparably small (e.g. 3 ng/L for hs-cTnT (Elecsys), 2 ng/L for hs-cTnI (Architect)). 
This might be problematic for two reasons: 1) cTnI concentrations appear to vary 
randomly over a 24h period, with a constant CVI (coefficient of variation within-
subject) of 8-9% for all time intervals, irrespective of underlying renal function (20,21) 
– whereas hs-cTnT follows a marked diurnal variation, characterised by a mean difference of 
4 ng/L between morning and evening samples in healthy volunteers (thus unlikely to affect 
delta-change values in clinical practise)(21);  2) within-subject coefficient of variation 
values (CVI) range from 3.4-24% for hs-cTnI (Architect) and 1.2-48.2% for hs-cTnT 
(Elecsys) even during short-term repeats.(22–24) In summary, this might affect the number 
of patients that benefit from the use of small delta-change values, given that most hs-cTn 
assays yield a CVA of ~20% below the 99
th
 centile – precisely the concentration range where 
the delta-change values are used to triage the individual with chest pain (see also Kavsak et 
al. (25)). Reassuringly however, this will tend to yield false-positives, rather than false-
negatives, as only patients with low baseline cTn without dynamic delta-change values 
qualify for rule-out. 
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 Chest pain triage and diagnosis of Acute Myocardial Infarction 
When cardiac Troponin was an insensitive assay, it was impossible to quantify the normal 
distribution in a reference population. Thus, the 99
th
 centile of a healthy reference-population 
was defined as a cut-off for an elevated result.(8,26) Arguably, the most common use of 
cardiac Troponin assays to date lies in chest pain triage – their relative sensitivity is 
unmatched by cardiac imaging techniques, which are incapable of detecting the small 
volumes of myocardial necrosis that will trigger a troponin rule-in decision.(18) Guidelines 
by the American Heart Association (AHA), American College of Cardiology (ACC) and 
European Society of Cardiology (ESC) endorse the use of hs-cTn, but frequently advocate 
decision limits which are widely-spaced around the 99
th
 centile for triage purposes.(16,17) 
This is to limit the downstream effect of using hs-cTn assays, which include (i) a 2-fold 
increase of detection of type 2 AMI, (ii) ~20% relative increase in detection of type 1 AMI 
and (iii) ‘elevations up to 3-fold the upper reference limit (URL), which,…may be associated 
with a broad spectrum of conditions’. (17) As the main purpose of these guidelines is the 
selection of patients with type 1 myocardial infarction (a plaque rupture event), triage 
focusses on risk-stratification into (safe) rule-out, and rule-in categories (with high PPV for 
AMI).  
In addition to guideline-endorsed pathways, there are a number of different strategies to 
facilitate safe and rapid rule-out – Mueller et al. have provided a summary in 2017 (27), and 
there are alternative approaches as used in the HighSTEACS and the ICare-ACS trials.(28–
30) Most pathways facilitate safe rule-out of AMI (with a Negative Predictive Value ≥99%), 
but with variable ‘triage efficacy’ – as determined by the number of patients which remain in 
an indeterminate ‘observe’ zone after applying the algorithm. Several publications have 
reported on the variable effectiveness of e.g. the ESC algorithm in clinical practice – many 
patients have to undergo a second blood draw in an attempt to increase efficiency of triage by 
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 migration from the ‘observe’ category of diagnostic uncertainty to either rule-out or -in. As 
few as 20-30% of patients benefit from immediate (i.e. on first blood draw) rule-out/-in using 
the cut-offs published.(31–33) In some healthcare environments, this poses logistical 
challenges for the Emergency Department – in an increasing number of countries, such as the 
US and the UK, performance targets concerning Emergency Care provision demand rapid 
triage, with an admit or discharge decision required within four hours of arrival to hospital. 
(34–36) In these countries, approaches that increase the number of patients eligible for direct 
rule-out (i.e. after a single blood test) would decrease pressures on strained resources. Shah et 
al. have demonstrated an increase in eligible patients with no significant reduction in safety 
(based on NPV >99%) by increasing the rule-out threshold using hs-cTnI (Abbott; from ESC 
at 2 ng/L) to 5 ng/L.(29) As any cut-off is assay-dependent, caution must be exercised when 
applying published algorithms to local practices.  
Using the ESC 0/1h pathway, 24-50% of patients remain in the ‘observe’ zone despite a 
second blood draw (table 1).(33,37) The cohorts studied are not homogenous, most simply 
demonstrated by the variable prevalence of AMI, which fluctuates between 4% in US and 
>17% in European populations.(38) The patients remaining in the ‘observe’ zone tend to be 
older, with pre-existing coronary artery disease, and 15% of this subgroup are ultimately 
diagnosed with AMI. While Nestelberger et al have described the patients in the 
‘observe’ zone as a heterogenous group with a rate of survival at 2 years (86%) similar to 
the ‘rule-in’ cohort (37), a recent analysis by Twerenbold et al quotes overall mortality 
after 1 year at 5.7-7.2%, depending on hs-cTn assay used for risk stratification (vs 8-
10.4% in the rule-in group).(39) The discrepancy might stem from a difference in length 
of follow-up and number of patients recruited, but emphasises that these patients are 
not at low risk of morbidity and mortality. An overview of the reported proportion of 
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 patients in the ‘observe’ zone from different studies/cohorts is provided in tables 1-
3.(36,37,48–57,40,58,41–47) 
One further concern affects the efficacy of hs-cTn pathways in patients with renal 
dysfunction – not only are the median cTn concentrations higher this group, but this 
population is also at increased risk of cardiovascular events.(59,60) Twerenbold et al. 
demonstrated that the prevalence of NSTEMI was substantially higher in patients with renal 
dysfunction (31% vs 13%); while safety of the 0/1h ESC pathway (as defined by sensitivity) 
was unaffected, triage efficacy suffered as only 18% of patients qualified for rule-out 
(compared to 68% in patients without underlying renal disease) – findings corroborated by 
Miller-Hodges et al.(46,61) 
In summary, hs-cTn assays enable safe rule-out (with NPV ≥99%) employing a number of 
different algorithms with varying degrees of overall efficacy. The application of rapid rule-
in/rule-out algorithms using 0/1h-repeat sampling accelerate the diagnostic pathway 
when compared to the use of contemporary cTn assays mandating 6-12 hour repeat 
testing. However, the algorithms for chest pain triage have become more complicated as 
more patients have quantifiable cTn concentrations, and conditions affecting baseline 
cardiovascular risk such as underlying renal dysfunction contribute significantly to a higher 
number of patients unsuitable for rule-out of AMI using very low hs-cTn concentrations. 
Furthermore, clear guidance is currently lacking to determine the most appropriate follow-up 
investigation to further risk-stratify patients with elevated cTn concentrations that do not 
fulfil rule-in criteria. In the acute setting, hs-cTn is therefore most useful when (nearly 
undetectably) low, or significantly elevated – in between, there remains a great amount of 
uncertainty, which to date can only be addressed with thorough clinical assessment and 
appropriate investigations on a case-by-case basis. 
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 Heart failure 
Detectable concentrations of circulating troponins below and above the 99
th
 percentiles of 
healthy populations are commonly found in patients with heart failure outside the context of 
an acute coronary syndrome. Reports on the incidence of troponin elevation in patients with 
heart failure vary depending on the population, the severity of heart failure, the sensitivity of 
assay used, and the cut-off points.(62) 
High sensitivity troponin assays allow the detection of circulating troponin in almost all 
patients with heart failure (63,64), with concentrations above the 99
th
 percentile found in the 
majority of patients with chronic (64,65), and nearly all patients with acute heart 
failure.(63,66)  
In those without clinical, electrocardiographic or imaging evidence of Type 1 MI (the classic 
plaque-rupture event), causes of troponin elevation remain elusive and speculative in the 
majority of cases. Suggested mechanisms include myocardial injury by inflammatory 
cytokines or oxidative stress, hibernating myocardium, apoptosis, increased plasma 
membrane permeability of viable injured cells (62), and stretch related mechanisms in viable 
non-injured cardiomyocytes mediated by integrins.(67)  
Whereas the therapeutic implications of identifying troponin elevation in the context of type 
1 MI compounded by heart failure is well-described, it has yet to be explored and established 
for all other causes. Irrespective of the underlying pathophysiology, troponin elevation in 
patients with heart failure has significant prognostic value: Numerous studies have reported a 
strong direct association between elevated troponin and the incidence of mid- to long-term 
adverse cardiovascular events, including all-cause mortality, cardiovascular death, worsening 
heart failure during index admission, rehospitalisation and cardiac transplantation, in both 
ischemic and non-ischemic heart failure.(63,64,75–79,65,68–74)  
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 Studies have also shown that serial testing of cardiac troponins in patients with 
decompensated and chronic heart failure may provide more robust prognostic information 
than a single measurement, as patients with increasing troponin concentrations have 
significantly worse outcomes than those with stable or decreasing values.(63,64)  
Additionally, minimally elevated troponins in otherwise healthy individuals (e.g. without pre-
existing ischaemic heart disease) may predict future development of heart failure.(80) 
In summary, beyond the context of acute myocardial infarction, and irrespective of the 
aetiology of heart failure, elevated cTn is an independent predictor of adverse outcomes in 
patients with heart failure. The impact on treatment and follow up is yet to be established in 
clinical trials. 
Renal failure 
Accurate interpretation of elevated cTn concentrations in the presence of renal disease is an 
everyday challenge and requires careful consideration of the clinical context. There are 
several contributing factors, including the increased likelihood of atypical presentations in 
this group (81) and the presence of chronically detectable troponin concentrations below and 
above the 99
th
 percentile in some patients with chronic renal disease. Furthermore, the exact 
pathophysiology of chronic stable cTn elevation, and whether this is due to reduced renal 
elimination or increased cardiac release caused by coexistent coronary artery disease and/or 
accumulating toxins, remain unclear.(82)  
As described above, significant heterogeneity exists between studies reporting on the 
diagnostic accuracy of hs-cTn in patients with renal disease and suspected myocardial 
infarction. Patients with end-stage renal failure and patients on dialysis were under-
represented in most studies, and caution is required extrapolating overall results, to this 
underrepresented subgroup. In summary, the safety of contemporary troponin-based 
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 diagnostic approaches is high, but the specificity of rule-in and overall efficacy are 
significantly decreased. Adjusting the cut-off thresholds did not improve their diagnostic 
performance.(61) However, there is a clear prognostic signal: Short- and long-term risk (for 
death or a subsequent cardiovascular event) for patients with renal disease and elevated 
troponins, is twice as high as for those without.(46)  
Stable coronary artery disease  
High sensitivity troponin assays allow the detection of circulating troponins in nearly all 
patients with stable coronary artery disease (CAD).(83–85) The cause for higher median 
concentrations of cTn in this cohort over ‘healthy’ individuals without underlying CAD is 
not yet identified: apoptosis, cardiomyocyte turnover, strain, increased cardiac mass and 
subclinical plaque rupture (86) have all been suggested. In patients with stable CAD referred 
for elective coronary angiography, a direct association between elevated circulating Troponin 
concentrations and the extent of coronary atherosclerosis and high-risk plaque phenotypes 
(assessed with intracoronary IVUS in a non-culprit coronary artery) has been 
demonstrated.(86)  
As observed in patients with renal dysfunction and heart failure, higher cTn values seem to 
translate into a worse prognosis even in the stable ambulatory patient. The magnitude of cTn 
elevation independently predicts risks of cardiovascular death and heart failure in patients 
with stable CAD.(84) The incremental change in troponin concentrations on serial testing 
also appears to be associated with a higher risk of adverse events than stable or decreasing 
trends.(87)   
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 Lowering troponin concentrations in asymptomatic individuals–a worthy 
goal? 
Several studies and post-hoc analyses highlighted the possibility of drug-induced 
modification of cTn release and thus a potential effect on future risk and prognosis in 
select groups, in a variety of settings.  
However, the debate continues about the mechanism by which drugs can modify cTn 
release and thus potentially lower future risk in a wide spectrum of cardiac disease. One 
recent proof-of-concept study in otherwise asymptomatic individuals is worth 
highlighting: would modifying cTn concentrations in patients without established coronary 
artery disease or heart failure affect their cardiovascular outcomes?                                       
WOSCOPS (West of Scotland Coronary Prevention Study) randomized men with raised 
low-density lipoprotein cholesterol (LDL) and no history of myocardial infarction to 
pravastatin 40 mg once daily or placebo for 5 years.(88,89) Ford et al. measured cTnI 
concentration with a high-sensitivity assay at baseline and at 1 year in 3,318 participants of  
WOSCOPS to establish whether cTnI values can be modified with statin therapy and 
whether the change in cTnI concentration is an independent predictor of future coronary 
risk, irrespective of cholesterol lowering. Indeed, cTnI concentrations fell in a presumed 
response to statin therapy, and the change in troponin concentration at 1 year was a strong 
predictor of nonfatal myocardial infarction or death from coronary heart disease. The additive 
decrements in future cardiovascular risk were independent of LDL cholesterol lowering.(89)  
However, only modest statin induced cTnI reduction was reported in stable patients with 
previous MI or unstable angina receiving pravastatin 40 mg in another prospective study.(87) 
Overall, the exact mechanism by which statin therapy might reduce cTn release is unclear; 
similarly, the underlying mechanism as to why statin-induced cTn reduction modifies future 
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 risk, regardless of cholesterol lowering is also unexplained. Irrespective of the mechanism, 
lowering cTn concentrations appears to be associated with an improved prognosis. 
Clearly, there is an ongoing need for robust data to determine underlying mechanisms 
and study the effects of different drugs in asymptomatic individuals for the purpose of 
primary prevention. 
Troponin release with exercise 
A significant increase in the serum concentrations of cTn after exercise, in otherwise healthy 
and asymptomatic individuals, is reported in numerous studies.(87,90–97) But the prevalence 
of cTn elevation among the study participants varies depending on the cohort, the type and 
intensity of exercise, and the assay used. The magnitude of cTn release did not correlate with 
the presence of conventional cardiac risk factors, but with younger age (98,99), less training 
and experience (90,98) and increased intensity of exercise.(94,97,99) Further, cTn elevation 
was associated with an alteration in cardiac function demonstrated on Cardiac Magnetic 
Resonance Imaging (cMRI). However, the findings varied in terms of anatomical location 
and degree of dysfunction across studies (88,90–93,100–102), and there was no evidence of 
associated myocardial oedema or fibrosis on cMRI (93,103–105). This supports the 
hypothesis that the cTn increase is likely due to a benign cytosolic release, secondary to 
increased cellular permeability, rather than a sinister ischaemic insult.(87,91,96) 
Nevertheless, the clinical significance of exercise-induced rises in cTn concentration remains 
unclear. In the absence of accompanying symptoms and signs of myocardial infarction or 
exercise induced myocarditis, post-exercise cTn rise should be interpreted carefully. 
Although highly increased cTn following exercise might suggest sub-clinical coronary artery 
disease in otherwise healthy individuals (95), prognostic value and possible preventive 
therapies are yet to be identified in this group. 
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 Conclusions 
Cardiac Troponin has transformed the provision of acute cardiac care – most notably, in the 
triage of patients presenting with chest pain, where novel rule-in/-out strategies speed up 
identification of individuals suitable for early discharge, and enhance the diagnosis of 
myocardial infarction. Owing to greater analytic sensitivity, the field has, however, became 
more blurred, and some might mourn the perceived loss of specificity in the diagnosis of 
AMI. This can be, to a certain degree, overcome by using decision thresholds for rule-in of 
AMI which are many-fold higher than the respective 99
th
 centile of the assay used – which 
invariably achieves higher specificity & PPV than a simple dichotomous threshold (such as 
the 99
th
 centile). As we discuss in this review, this results in a variable proportion of patients 
assigned to an ‘observe’ zone, where diagnostic clarity is lost and thorough clinical 
assessment, the use of imaging modalities and re-testing are required to guide further 
treatment. The former – the clinical assessment – is enhanced by the knowledge that hs-cTn 
assays yield a quantifiable result in most patients seen in daily clinical practice: in those with 
heart failure, renal dysfunction, stable coronary artery disease, following relatively intense 
exercise; and in rare cases due to analytical (im-)precision and biological variation. The 
physician should be comfortable with the interpretation of cardiac biomarkers in a similar 
fashion as they understand reference ranges for blood counts, so deriving most benefit from 
increased sensitivity, accelerated decision pathways and enhanced risk prediction. The latter 
underlines the incredible value high-sensitivity assays bring to the diagnostic arsenal: an 
elevation in the cardiac biomarker profile is meaningful as it tracks risk for future morbidity 
and mortality. Whilst we need to strive for a better understanding of the exact mechanisms 
that underlie a ‘chronically elevated’ cTn concentration, such a finding alone should 
probably prompt a comprehensive cardiovascular workup, to exploit all opportunities in 
modifying future risk using established therapies that impart prognostic benefit. But, the 
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 myth of ‘false-positives’ can – and should in most cases – be laid to rest, to be replaced by an 
understanding of a true biological signal that cTn offers. 
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Patient category after 0/1h hs-cTn   MI prevalence by category Comments/Assay 
Study/Centre n Obs (%) RO (%) RI (%) Age 
CAD 
(%) 
MI 
(%) 
Obs (%) 
RO 
(%) 
RI (%) 
 
39 APACE 
Multicentre - 
IT, CH, ES 
1656 24.1 59.5 16.4 60  
[49-74] 
33.3 17.3 18 0.13 78.24 A1 
40a Multicentre - 
NZ, CA, AU 
2222 22.7 64.1 13.1 59  
(SD 14) 
* 9.7 9.5 0.49 63.36 a = hs-cTnT cohort; A1 
40b Multicentre - 
NZ, CA, AU 
2222 31.8 54.2 14.0 59  
(SD 14) 
* 9.7 9.5 0.25 68.06 b = hs-cTnI cohort; A2 
41 APACE 
Multicentre 
436 23.2 59.4 17.4 63  
[50-75] 
36 17 8 0.00 84.21 Validation cohort; A1 
42 TRAPID-
AMI 
Multicentre 
1282 22.2 63.4 14.4 62  
[50-74] 
36.9 17 22.5 0.86 77.17 A1 
45a APACE 
Multicentre 
European 
cohort 
2767 18.5 67.9 13.3 58  
[47-70] 
29 13 15 0.16 77.11 Using data set A from 
trial with normal renal 
function; A1 
45b APACE 
Multicentre 
European 
cohort 
487 48.7 18.1 33.3 79  
[73-84] 
57 31 11 0.00 76.54 Using data set A from 
trial with abnormal renal 
function; A1 
45c APACE 
Multicentre 
European 
cohort 
2504 23.9 57.8 18.3 58  
[47-70] 
29 13 15 0.48 60.70 Using data set B from 
trial with normal renal 
function; A2 
45d APACE 
Multicentre 
European 
cohort 
445 46.5 17.3 36.2 79  
[73-84] 
58 31 13 2.60 70.81 Using data set B from 
trial with abnormal renal 
function; A2 
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 51 Multicentre – 
JP, TW 
413 27.8 41.4 30.8 72  
[59-81] 
24.5 13.8 17.4 0.00 33.07 exclusively Asian 
population; A1 
Table 1 – Overview of studies modelled on ESC 0/1h rule-out/rule-in algorithm; Ref = Reference as per quotation in 
main text; Obs = Observation group; RO = Rule-Out group; RI = Rule-In group; Age quoted as Median [IQR] unless 
stated otherwise; CAD = Coronary Artery Disease; MI = Myocardial Infarction; IT = Italy; CH = Switzerland; ES = 
Spain; NZ = New Zealand; CA = Canada; AU = Australia; JP = Japan; TW = Taiwan; SE = Sweden; A1 = Elecsys hs-cTnT; 
A2 = Architect hs-cTnI 
 
Ref 
 
Patient category after 0/2h algorithm   MI prevalence by category Comments/Assay 
Study/Centre n Obs (%) 
RO 
(%) 
RI 
(%) 
Age 
CAD 
(%) 
MI 
(%) 
Obs 
(%) 
RO 
(%) 
RI (%) 
 
53a APACE 
Multicentre 
1148 24.2 59.5 16.3 62 [51-74] 36 16 15 0.15 78.07 Derivation cohort; A1 
53b APACE 
Multicentre 
517 14.5 77.8 7.7 54 [45-65] 26 9.1 15 0.50 85.00 Validation cohort; A1 
54a APACE 
Multicentre - 
European cohort 
1435 27.2 56.0 16.7 62 [49-74] 35 17 14 0.25 75.83 Derivation cohort 0/2h 
algorithm; A2 
54b APACE 
Multicentre - 
European cohort 
1194 27.4 59.9 12.7 61 [50-73] 21 13 9 0.28 82.24 Validation cohort 0/2h 
algorithm; A3 
55 ADAPT cohort - 
AU, NZ 
1624 31.0 58.7 10.3 60.5 (SD 15) 45.8 13.9 14.5 0.73 86.31 Biomarker + ECG algorithm; 
A3 
57 Multicentre - UK 722 25.1 58.4 16.5 58.8 [51-69] * 13.7 4.4 0.24 58.82 A1 
56 Multicentre - SE 605 25.5 61.8 12.7 65 [54-75] 24.9 14.2 10.4 0.80 87.01 Derivation cohort; A4 
Table 2 – Overview of studies using 0/2h rule-out/rule-in algorithm; Ref = Reference as per quotation in main text; 
Obs = Observation group; RO = Rule-Out group; RI = Rule-In group; Age quoted as Median [IQR] unless stated 
otherwise; CAD = Coronary Artery Disease; MI = Myocardial Infarction; IT = Italy; CH = Switzerland; ES = Spain; NZ = 
New Zealand; CA = Canada; AU = Australia; JP = Japan; TW = Taiwan; SE = Sweden; A1 = Elecsys hs-cTnT; A2 = 
Architect hs-cTnI; A3 = Vista hs-TnI; A4 = Vidas hs-cTnI 
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 Ref 
 
Patient category after algorithm   MI prevalence by category Comments/Assay 
Study/Centre n Obs (%) RO (%) RI (%) Age 
CAD 
(%) 
MI 
(%) 
Obs 
(%) 
RO 
(%) 
RI (%) 
 
48 APACE 
Multicentre 
649 23.0 64.7 12.3 62 [50-74] 35 17 14.8 1.43 76.25 Validation cohort; A5 
46 Multicentre - AU, 
NZ (ADAPT, 
EDACS) 
2537 43.4 42.9 13.8 62 [49-75] 35 18 10.0 0.46 83.95 Combination A1+A2 at 
presentation; validation 
cohort 
43 APACE 
Multicentre - IT, 
CH, ES 
905 30.5 50.5 19.0 62 [50-74] 37 19 13.0 0.44 76.00 Validation cohort; 0h hs-
cTnI <5 ng/L for RO, 
delta 1h ≥6 ng/L for RI; 
A2 
44 APACE 
Multicentre - IT, 
CH, ES 
750 29.9 57.1 13.1 60 [48-72] 32 13 13.0 0.00 70.00 Validation cohort; A3 
36 Single centre - St 
Thomas' Hospital, 
UK 
4644 51.9 40.4 7.7 54 [41-70] * 21.2 * * * Presentation sample (0h) 
only; A1 
47a APACE 
Multicentre - CH, 
IT, PL, ES, CZ 
1416 63.5 23.4 13.1 62 (SD 16) 36 17 11.0 0.00 81.08 A1 cohort with chest 
pain for ≥3 hours; 
presentation (0h) sample 
only 
47b APACE 
Multicentre - CH, 
IT, PL, ES, CZ 
1397 70.5 13.2 16.3 63 (SD 16) 36 17 11.0 0.00 71.49 A2 cohort with chest 
pain for ≥3 hours; 
presentation (0h) sample 
only 
49a Multicentre - CA 1137 35.1 52.5 12.4 66.6 (SD 
16.3) 
36 11.7 14.3 1.68 46.81 taken from Algorithm 4 
data, modified ESC 
algorithm; A1 
49b Multicentre - CA 1137 47.6 44.3 8.1 66.6 (SD 
16.3) 
36 11.7 11.5 0.79 72.83 taken from Algorithm 4 
data, modified ESC 
algorithm; A2 
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 50 Single centre - 
Manchester Royal 
Infirmary, UK 
703 42.1 27.7 30.2 58.6 (SD 
14.3) 
23.8 18 6.4 0.00 52.36 Using 3-14 ng/L as 
observe zone for 0/1h 
cTn; A1; additional 
computer model 
Table 3 – Overview of studies using modified rapid rule-out/rule-in algorithms; Ref = Reference as per quotation in 
main text; Obs = Observation group; RO = Rule-Out group; RI = Rule-In group; Age quoted as Median [IQR] unless 
stated otherwise; CAD = Coronary Artery Disease; MI = Myocardial Infarction; IT = Italy; PL = Poland; CH = 
Switzerland; ES = Spain; NZ = New Zealand; CA = Canada; AU = Australia; JP = Japan; TW = Taiwan; SE = Sweden; A1 = 
Elecsys hs-cTnT; A2 = Architect hs-cTnI; A3 = Vista hs-TnI; A4 = Vidas hs-cTnI; A5 = ADVIA Centaur s-cTnI; * Data not 
available 
 
Ac
ce
pte
d M
an
us
cri
pt
